Skip to main content
OpenTrials
Completed

NCT Number: NCT03889834

Biological Parameters Changes After Autologous Blood Transfusion of Red Blood Cells (200 ml) in Healthy Volunteers.

The purpose of this study is to evaluate if differences between samples of subjects obtained before autologous blood transfusion or samples of non-transfused subjects and samples of subjects after autologous blood transfusion can be identified. Analyses performed will focus on the morphological and biochemical parameters of red blood cells and associated microparticles. The final goal would be to find markers of autologous blood transfusion, that could be used to identify such doping practice.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–35 year

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Primary location

EFS de Versailles, centre de soins

Chesnay, Île-de-France Region, 78150, France

About this study

Methodology and study design:

Pr Olivier Hermine, coordinator of the laboratory of Excellence GR-EX regrouping EFS (Etablissement Français du Sang) and INSERM (Institut National de la Santé et de la Recherche Médicale) partners, and leader of the Centre d'Investigation Clinique (CIC) Necker (Hospital Necker, Paris, France) will assure the promotion of the clinical study for Paris Hospital consortium AP-HP (assistance Publique-Hôpitaux de Paris).

To reproduce two potential scenarios of autologous transfusion by an athlete, 1 bag of blood packed red blood cells (after leuko deprivation and centrifugation) will be either stored at 4°C or frozen at -80°C after addition of 40% w/v glycerol. Reinfusion will be performed 33 days later.

A clinical randomized double-blinded two-phase study will be conducted. Volunteers will be separated in 3 groups:

  • Group 1: Volunteers with regular sports activities without Autologous Blood Transfusion (ABT)T (n=10)
  • Group 2: Volunteers with regular sports activities receiving a 200ml ABT with refrigerated blood (n=10)
  • Group 3: Volunteers with regular sports activities receiving a 200ml ABT with frozen blood (n=10)

To ensure volunteers safety, collection, preparation and pretransfusion blood testing will be performed by EFS (Versailles, France). ABT as well as collection of samples will be performed at the CIC Necker (Paris, France). Blood samples will be collected before blood removal, the day of the ABT just before reinfusion and after 3 hours, 8 hours, 24 hours and 48 hours post-ABT. To perform all the experiments 25ml blood (4x 5 ml BD Vacutainer EDTA tubes) will be taken at each time point:

1 will be dispatched to the French anti-doping laboratory (LADF) for haematological analysis (Orsay, France), 2 to the EFS (Créteil, France) for RBC and MPs morphological characterization and quantification (using antigen markers, band 3 on the surface of MPs), 2 to INTS for MPs isolation, characterization (band 3 on the surface of MPs and RBC) and for proteomic analysis and Western-Blot.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male between 18 and 35 years old
  • Without health problem nor disease requiring regular medical treatment
  • Free from any intercurrent acute pathology over 7 days
  • Healthy volunteers who have regularly sport activity, able to have blood sample and is out-of-competition during the research
  • Subject who did not practice a competition (or exhaustive training ) 3 days before the blood sample and the autotransfusion
  • Affiliated to a social security regimen

Exclusion criteria

  • Subject with contraindication for drawing blood
  • Subject with medical pathology contraindicating sport practice
  • Subject under treatments or drugs in the list of products prohibited for sports practice and competitions, in particular erythropoeitins and erythropoiesis-stimulating agents (updated list of World Anti-Doping Agency https://www.wada-ama.org/fr/liste-des-restrictions).
  • Subject with physical or mental disability or restriction of liberty that would prevent autotransfusion
  • Subject without a social security regimen
  • Subject under guardianship or curatorship
  • Subject participating in any Interventional study
  • Positive HIV and/or hepatitis serology
  • Discovery of a hematological disease

Treatment and study plan

Autologous blood transfusion

Procedure

Autotransfusion of packed red blood cells (200 ml) stored at 4 or -80°C for 33 days

No transfusion

Other

no transfusion

Primary outcomes

  1. Change in hematological parameters

    Time frame: Baseline (Day 1), until 2 days after autotransfusion

    erythrocytes (/µL)

  2. Change in hematological parameters

    Time frame: Baseline (Day 1), until 2 days after autotransfusion

    hemoglobin (g/dL)

  3. Change in hematological parameters

    Time frame: Baseline (Day 1), until 2 days after autotransfusion

    Hematocrit (%)

  4. Change in hematological parameters

    Time frame: Baseline (Day 1), until 2 days after autotransfusion

    Mean corpuscular volume (fL)

  5. Change in hematological parameters

    Time frame: Baseline (Day 1), until 2 days after autotransfusion

    Reticulocyte by Sysmex analyzer

  6. Variation in Red blood cells morphology

    Time frame: Baseline (Day 1), until 2 days after autotransfusion

    By amnis imaging flow cytometryProteins in Red blood cells (Wblot/ELISA/FACS)

  7. Change in expression of cell surface proteins in red blood cells transfusion

    Time frame: Baseline (Day 1), until 2 days after autotransfusion

    Western blot /ELISA/ fluorescence-activated cell sorting of red blood cells

  8. Change in microparticles detected in plasma

    Time frame: Baseline (Day 1), until 2 days after autotransfusion

    fluorescence-activated cell sorting

Secondary outcomes

  1. Change in phthalate in urine

    Time frame: Baseline (Day 1), until 2 days after autotransfusion

    Assay by LC-MS/MS in urine

Sponsors and collaborators

Lead sponsor

Assistance Publique - Hôpitaux de Paris

Other

Collaborators

  • Etablissement Français du Sang
  • GR-Ex executive comitee
  • Institut National de la Santé Et de la Recherche Médicale, France
  • Laboratoire antidopage français (LADF)
  • URC-CIC Paris Descartes Necker Cochin
  • World Anti-Doping Agency

Registry information

Official study title

Modification of Biological Parameters After Autologous Blood Transfusion of a Small Volume of Packed Red Blood Cells (200 ml) in Healthy Volunteers

Acronym: AUTOT-SPORT

Important dates

Study start
2024
Primary completion
2025
Study completion
2026
First posted
Mar 26, 2019
Registry last updated
Apr 23, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.